Supernus Pharmaceuticals, Inc. (SUPN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Supernus Pharmaceuticals reported revenue of $719.0M, up 8.6% from $661.8M the year before. Net income was -$38.5M (a -5.4% net margin), or -$0.68 per diluted share. Gross margin was 89.6% and operating margin was -8.7%. Operating activities generated $47.3M of cash, leaving $46.0M of free cash flow. At fiscal year end, Supernus Pharmaceuticals held $1.45B in total assets against $390.9M in total liabilities, including $128.4M of cash and equivalents.
Open the full interactive Supernus Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Supernus Pharmaceuticals Key Stats
| Share Price | $42.01 |
|---|---|
| Market Cap | $2.44B |
| Revenue YoY Growth | +8.6% |
| 52-Week Range | $41.28 – $57.00 |
| Shares Outstanding | 58.1 million (basic, 2026 Q2) |
Supernus Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| Cost of Goods Sold | $52.5M | $493.7M | $621.1M | $612.8M | $77.9M | $74.6M |
| Gross Profit | $467.9M | $86.0M | $46.1M | -$5.3M | $583.9M | $644.4M |
| Operating Income | $173.7M | $86.0M | $46.1M | -$5.3M | $81.7M | -$62.3M |
| Pre-Tax Income | $168.6M | $73.2M | $60.7M | $2.8M | $97.9M | -$49.0M |
| Income Tax | $41.7M | $19.8M | $32,000 | $1.5M | $24.0M | -$10.5M |
| Net Income | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | -$38.5M |
| Diluted EPS | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 |
Supernus Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $192.1M | $211.6M | $207.7M | $219.1M |
| Net Income | -$45.1M | -$4.1M | -$2.3M | -$58.4M |
| Diluted EPS | -$0.80 | -$0.07 | -$0.04 | -$1.01 |
Supernus Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $288.6M | $203.4M | $93.1M | $75.1M | $69.3M | $128.4M |
| Current Assets | $630.4M | $601.6M | $734.2M | $493.1M | $686.1M | $644.2M |
| Total Assets | $1.50B | $1.69B | $1.70B | $1.28B | $1.37B | $1.45B |
| Current Liabilities | $245.1M | $315.4M | $688.0M | $290.2M | $292.4M | $338.2M |
| Total Long-Term Debt | $361.8M | $379.3M | — | — | — | — |
| Total Liabilities | $759.2M | $873.3M | $816.3M | $356.2M | $332.3M | $390.9M |
| Shareholders' Equity | $744.9M | $815.9M | $886.2M | $921.5M | $1.04B | $1.06B |
Supernus Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $138.4M | $127.1M | $116.8M | $111.1M | $172.0M | $47.3M |
| Cash From Investing | -$34.7M | -$81.9M | -$216.7M | $268.7M | -$189.9M | $4.1M |
| Cash From Financing | $3.6M | -$130.4M | -$10.5M | -$397.9M | $12.2M | $9.1M |
| Free Cash Flow | $134.9M | — | — | — | $171.2M | $46.0M |
Figures from Supernus Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Supernus Pharmaceuticals financials page for every line item.
Supernus Pharmaceuticals Company Profile
| Ticker | SUPN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Rockville, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001356576 |
Frequently Asked Questions
What was Supernus Pharmaceuticals' revenue in fiscal 2025?
Supernus Pharmaceuticals (SUPN) reported revenue of $719.0M for fiscal 2025.
What is Supernus Pharmaceuticals' annual revenue history?
Supernus Pharmaceuticals' annual revenue by fiscal year: 2020: $520.4M; 2021: $579.8M; 2022: $667.2M; 2023: $607.5M; 2024: $661.8M; 2025: $719.0M.
What was Supernus Pharmaceuticals' net income in fiscal 2025?
Supernus Pharmaceuticals reported net income of -$38.5M for fiscal 2025.
What was Supernus Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Supernus Pharmaceuticals' diluted EPS was -$0.68 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Supernus Pharmaceuticals generate in fiscal 2025?
Supernus Pharmaceuticals generated $46.0M of free cash flow in fiscal 2025.
What was Supernus Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Supernus Pharmaceuticals reported revenue of $219.1M.
How many shares of Supernus Pharmaceuticals are outstanding?
Supernus Pharmaceuticals reported a weighted average of 58.1 million basic shares outstanding in 2026 Q2.
What is Supernus Pharmaceuticals' market cap?
Based on its latest closing price, Supernus Pharmaceuticals (SUPN) has a market capitalization of about $2.44B.
When does Supernus Pharmaceuticals' fiscal year end?
Supernus Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals lists its business address in Rockville, Maryland in its SEC filings.